Fig. 4: MYSM1 reduces cisplatin resistance by RSK3 inactivation and decreased phospho-BAD (Ser 112).
From: MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
A MYSM1 overexpressed and knockdown MDA-MB-231 and Hs578T cells and their corresponding negative control cells were treated with or without cisplatin (5 µg/mL) for 48 h. The whole-cell lysate was collected to extract mRNA, and quantitative real-time qPCR was performed to detect mRNA levels. B MYSM1 overexpressed and knockdown MDA-MB-231 and Hs578T cells and their corresponding negative control cells were treated with or without cisplatin (5 µg/mL) for 48 h. The whole-cell lysate was collected to extract protein, and western blot was performed to detect protein levels. C MDA-MB-231 and Hs578T cells were treated with cisplatin (5 µg/mL) for 48 h. RSK3 was immunoprecipitated with an RSK3-specific antibody. Endogenous RSK3 and phospho-BAD (Ser 112) were determined via western blot. D, E Following the corresponding treatments, cells were treated with cisplatin (5 µg/mL) for 48 h. Protein levels were detected by western blotting analysis. All data in the graph bars represent means ± SD. *P < 0.05 and **P < 0.01.
